GSK R&D vet Rus­so jumps to Genen­ta, takes a lead role in de­vel­op­ing a new gene ther­a­py

GSK vet Car­lo Rus­so is join­ing up with some of his for­mer gene ther­a­py col­leagues, tak­ing the chief med­ical of­fi­cer’s role at Mi­lan-based Genen­ta Sci­ence.

Rus­so is com­ing over di­rect­ly from Ad­verum, but ear­li­er worked at GSK as head of R&D for their rare dis­ease unit. Rus­so and Genen­ta co-founder Lui­gi Nal­di­ni had crossed paths be­fore at the San Raf­faele Hos­pi­tal in Mi­lan, a pi­o­neer in gene ther­a­py. A col­lab­o­ra­tion be­tween San Raf­faele and GSK led to the ap­proval of Strimvelis last year, which is look­ing to be­come used in Eu­rope for a rare dis­ease called ADA-SCID (se­vere com­bined im­mun­od­e­fi­cien­cy due to adeno­sine deam­i­nase de­fi­cien­cy.)

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER